Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Animal Pharmacology of Nebivolol

  • 11 Accesses

  • 10 Citations

Summary

Nebivolol is a mixture of equal amounts of 2 enantiomers: SR3-nebivolol (d-nebivolol) and RS3-nebivolol (l-nebivolol). SR3-nebivolol is a potent and selective β1-adrenergic antagonist both in vitro and in vivo. Nebivolol acutely lowers blood pressure in spontaneously hypertensive rats and induces a slight decrease in total peripheral vascular resistance and a slight increase in cardiac output in anaesthetised dogs. These haemodynamic effects cannot be explained by β1-adrenergic antagonism and are largely attributable to RS3-nebivolol.

This is a preview of subscription content, log in to check access.

References

  1. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. British Journal of Pharmacology 88: 411–415, 1986

  2. Blankestijn PJ, Tulen J, Boomsma F, van Eck HJR, Mulder P, et al. Support for adrenaline-hypertension hypothesis: 18 hour pressor effects after 6 hours adrenaline infusion. Lancet 2: 1386–1388, 1988

  3. Clarke DE, Bond RA, Charlton KG, Blue DR. Pre-synaptic 5-HT receptors mediating inhibition of transmitter release from peripheral cholinergic and noradrenergic nerves. In Mylecharane EJ et al. (Eds) Serotonin. Actions, receptors, pathophysiology, pp. 48–55, MacMillan Press Ltd, London, 1989

  4. De Clerck F, Van Gorp L, Loots W, Janssen PAJ. Differential effects of nebivolol, atenolol and propranolol on heart rate and on bronchoconstrictor responses to histamine in the guinea-pig. Archives Internationales de Pharmacologie et de Thérapie 298: 230–236, 1989

  5. Fozard JR, Kilbinger H. 8-OH-DPAT inhibits transmitter release from guinea-pig enteric cholinergic neurons by activating 5-HT1A receptors. British Journal of Pharmacology 86: 601P, 1985

  6. Fozard JR, Mir AK, Middlemiss DN. Cardiovascular response to 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. Journal of Cardiovascular Pharmacology 9: 328–347, 1987

  7. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB Journal 3: 2007–2018, 1989

  8. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373–376, 1980

  9. Heimburger M, Montero MJ, Fougeres V, Beslot F, Davy M, et al. Presynaptic β-adrenoceptors in rat atria: evidence for the presence of stereoselective β1-adrenoceptors. British Journal of Pharmacology 98: 211–217, 1989

  10. Janssens WJ, Van de Water A, Xhonneux R, Reneman RS, Van Nueten JM, et al. Nebivolol is devoid of intrinsic sympathomimetic activity. European Journal of Pharmacology 159: 89–95, 1989

  11. Kubo T, Kuwahara M, Misu Y. Effect of isoproterenol on vascular adrenergic neurotransmission in prehypertensive and hypertensive spontaneously hypertensive rats. Japanese Journal of Pharmacology 36: 419–421, 1984

  12. Loots W, De Clerck F. Differential effects of nebivolol, propranolol and phentolamine on adrenoceptors in the heart and in skeletal resistance arterioles in the rat. A quantitative intravital microscopical analysis. European Journal of Pharmacology 179: 177–186, 1990

  13. Lu HR, Vandeplassche G, Wouters L, Borgers M. β-Blockade in the ischemic reperfused working rabbit heart: dissociation of β-adrenergic blocking and protective effects. Archives Internationales de Pharmacodynamie et de Thérapie 301: 165–181, 1989

  14. Majewski H, Alade PI, Rand MJ. Adrenaline and stress-induced increases in blood pressure in rats. Clinical and Experimental Pharmacology and Physiology 13: 283–288, 1986

  15. Majewski H, Rand MJ. Prejunctional β-adrenoceptors and hypertension: a hypothesis revisited. Trends in Pharmacological Sciences: 500–502, 1984

  16. Majewski H, Rand MJ, Tung L-H. Activation of prejunctional β-adrenoceptors in rat atria by adrenaline applied exogenously or released as a co-transmitter. British Journal of Pharmacology 73: 669–679, 1981a

  17. Majewski H, Tung L-H, Rand MJ. Hypertension through adrenaline activation of prejunctional β-adrenoceptors. Clinical and Experimental Pharmacology and Physiology 8: 463–468, 1981b

  18. Majewski H, Tung L-H, Rand MJ. Adrenaline-induced hypertension in rats. Journal of Cardiovascular Pharmacology 3: 179–185, 1981c

  19. Majewski H, Tung L-H, Rand MJ. Adrenaline activation of prejunctional β-adrenoceptors and hypertension. Journal of Cardiovascular Pharmacology 4: 99–106, 1982

  20. Manin’t Veld AJ, Schalekamp MADH. How β-blockers lower blood pressure: divulgence of the non-essentiality of the cardiodepression and renin suppression by partial agonism and the key role of vascular resistance changes. Vascular Medicine 1: 195–218, 1983

  21. Manin’t Veld AJ, van den Meiracker A, Schalekamp MADH. The effect of β-blockers on total peripheral resistance. Journal of Cardiovascular Pharmacology 8: S49–S60, 1986

  22. Misu Y, Kaiho M, Yasuda G, Kuwahara M, Kubo T. Pharmacological properties of presynaptic β-adrenoceptors in guinea-pig pulmonary arteries. Japanese Journal of Pharmacology 36: 329–337, 1984

  23. Misu Y, Kuwahara M, Amano H, Kubo T. Evidence for tonic activation of prejunctional β-adrenoceptors in guinea-pig pulmonary arteries by adrenaline derived from the adrenal medulla. British Journal of Pharmacology 98: 45–50, 1989

  24. Misu Y, Kuwahara M, Kubo T. Some relevance of presynaptic β-adrenoceptors to development of hypertension in spontaneously hypertensive rats. Archives Internationales de Pharmacodynamie 287: 299–308, 1987

  25. Pauwels PJ, Gommeren W, Van Lommen G, Janssen PAJ, Leysen JE. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various β-adrenergic blockers. Molecular Pharmacology 34: 843–851, 1988

  26. Pauwels PJ, Leysen JE, Janssen PAJ. β-Adrenoceptor-mediated cAMP accumulation in cardiac cells: effects of nebivolol. European Journal of Pharamcology 172: 471–479, 1989

  27. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. British Journal of Pharmacology 92: 181–187, 1987

  28. Richardson BP, Hoyer D. Selective agonists and antagonists at 5-hydroxytryptamine receptor subtypes. In Paoletti R et al. (Eds) Serotonin. From cell biology to pharmacology and therapeutics, pp. 265–276, Kluwer Academic Publishers, Dordrecht, 1990

  29. Schlicker E, Erkens K, Göthert M. Probable involvement of vascular angiotensin II formation in the β2-adrenoceptor-mediated facilitation of the neurogenic vasopressor response in the pithed rat. Naunyn-Schmiedeberg’s Archives of Pharmacology 338: 536–542, 1988

  30. Schneider J, Fruh C, Wilffert B, Peters T. Effects of the selective β1-adrenoceptor antagonist, nebivolol, on cardiovascular parameters in the pithed normotensive rate. Pharmacology 40: 33–41, 1990

  31. Van de Water A, Janssens W, Van Nueten J, Xhonneux R, De Crée J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. Journal of Cardiovascular Pharmacology 11: 552–563, 1988a

  32. Van de Water A, Xhonneux R, Reneman RS, Janssen PAJ. Cardiovascular effects of dl-nebivolol and its enantiomers — a comparison with those of atenolol. European Journal of Pharmacology 156: 95–103, 1988b

  33. Vincent HH, Boomsma F, Manin’t Veld AJ, Schalekamp ADH. Stress levels of adrenaline amplify the blood pressure response to sympathetic stimulation. Journal of Hypertension 4: 255–260, 1986

  34. Xhonneux R, Wouters L, Reneman RS, Janssen PAJ. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer. European Journal of Pharmacology 181: 261–265, 1990

Download references

Author information

Correspondence to Dr W. J. Janssens.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Janssens, W.J., Xhonneux, R. & Janssen, P.A.J. Animal Pharmacology of Nebivolol. Drug Invest 3, 13–24 (1991). https://doi.org/10.1007/BF03258258

Download citation

Keywords

  • Isoprenaline
  • Drug Invest
  • Nebivolol
  • Cardiovascular Pharmacology
  • Adrenergic Antagonist